

ASX Announcement

Race Executes Key Contract for Israel Phase 2 AML Trial

- Contract signed to support Race's Phase 2 relapsed/refractory Acute Myeloid Leukemia (AML) trial at the Chaim Sheba Medical Center in Israel
- Trialog Clinical Trials Ltd to supply trial drugs and provide other clinical services
- Clinical trial contract is in final stages with the first patient expected to be treated in Q3 CY 2021

8 June 2021 – Race Oncology Limited (“Race”) is pleased to announce it has executed a contract with Trialog Clinical Trials Ltd, Israel, to support the coming combination Phase 2 Acute Myeloid Leukaemia trial. Trialog will supply the trial drugs (including Bisantrone) as well as provide other clinical services to Race and Chaim Sheba.

This 29 patient Phase 2 trial will use Bisantrone in a novel three drug combination which in preclinical studies showed superior efficacy in AML cells (ASX Announcement: 10 May 2021). The trial has received human ethics approval and will be supervised by Professor Arnon Nagler of the Chaim Sheba Medical Center. The first patient is expected to be treated in Q3 CY 2021.

The supply agreement has a maximum cost of USD\$801,247 and will be invoiced in line with patient enrolment over the period 2021 – 2023.

Race Oncology looks forward to advising on the initiation of this trial in the near future, once it has executed the trial contract with the Chaim Sheba Medical Center.

This Phase 2 AML trial will run in parallel with a separate Australian Phase 2 trial in patients with extramedullary AML that is expected to begin treating patients in Q4 CY 2021 (ASX announcement: 2 June 2021).

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrone.

Bisantrone is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Bisantrone as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Bisantrone as a



chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Bisantrene.

See more at www.raceoncology.com.

Release authorised by:

Phil Lynch, CEO/MD on behalf
of the Race Board of Directors
phillip.lynch@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au